• Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen, Denmark, said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended marketing authorization for Abilify Maintena (aripiprazole), an intramuscular depot formulation for maintenance treatment of schizophrenia in adults stabilized with oral aripiprazole.